Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Ken Flanagan, PhD, Muntasir M Majumder, MSc, BPharm, Romika Kumari, PhD, Juho Miettinen, PhD, Ana Slipicevic, PhD, Sarah A. Holstein, MD PhD, Michelle L. Varney, MS, Minna Suvela, MSC, Fredrik Lehmann, PhD, Nina N. Nupponen, PhD, Caroline A Heckman, PhD

Blood (2019) 134 (Supplement_1): 3100.

https://doi.org/10.1182/blood-2019-125952

Published: 2019

Journal Articles

MetAP2 Inhibition Modifies Hemoglobin S (HbS) to Delay Polymerization and Improve Blood Flow in Sickle Cell Disease

Melanie Demers, PhD, Sarah Sturtevant, BSc, Kevin Guertin, PhD, Dipti Gupta, Kunal Desai, MS, Benjamin Vieira, BS, Alexandra Hicks, PhD, Ayman Ismail, PhD, Yukio Nakamura, MD PhD, Bronner Goncalves, MD PhD, Giuseppe Di Caprio, PhD, Ethan Schonbrun, PhD, Scott Hansen, BS, Martin K. Safo, PhD, David K. Wood, PhD, John M. Higgins, MD PhD, David R. Light, PhD

Blood (2019) 134 (Supplement_1): 2260.

https://doi.org/10.1182/blood-2019-128727

Published: 2019

Journal Articles

Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells

Jacqueline Cloos, PhD, Godefridus J Peters, PhD, Marjon Al, BSc, Yehuda G Assaraf, PhD, Lixia Wang, PhD, Jack W. Singer, MD, Jorge E. Cortes, MD, Gert J. Ossenkoppele, MD PhD, Gerrit Jansen, PhD

Blood (2018) 132 (Supplement 1): 3945.

https://doi.org/10.1182/blood-2018-99-114447

Published: 2018

Journal Articles

OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS

Blood (2018) 132 (Supplement 1): 600.

https://doi.org/10.1182/blood-2018-99-113095

Published: 2018

Journal Articles

The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data

Blood (2018) 132 (Supplement 1): 1967.

https://doi.org/10.1182/blood-2018-99-112983

Published: 2018

Journal Articles

Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy

Sangmin Lee, MD, Pinkal Desai, MDMPH, Bianca Edirisinghe, Samantha Pianello, Jack W. Singer, MD, Michael Samuel, MD, Ellen K Ritchie, MD, Gail J. Roboz, MD

Blood (2017) 130 (Supplement 1): 2966.

https://doi.org/10.1182/blood.V130.Suppl_1.2966.2966

Published: 2017

Journal Articles

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Rakesh Popat, Sarah R Brown, Avie-Lee Tillotson, Fiona Collinson, Louise M Flanagan, Cathy D Williams, Kwee L Yong, Gordon Cook, MD PhD, Matthew W Jenner, MD, Martin Kaiser, Jim Cavet, FRCPath, Dima El-Sharkawi, MD, Chin-Hin Ng, MD MRCP, FRCPATH, Eric Low, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 3321.

https://doi.org/10.1182/blood.V128.22.3321.3321

Published: 2016

Journal Articles

Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML

Blood (2015) 126 (23): 329.

https://doi.org/10.1182/blood.V126.23.329.329

Published: 2015

Journal Articles

How I treat refractory and early relapsed acute myeloid leukemia

Felicitas Thol, Richard F. Schlenk, Michael Heuser, Arnold Ganser

Blood (2015) 126 (3): 319–327.

https://doi.org/10.1182/blood-2014-10-551911

Published: 2015

Journal Articles

Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma

Muntasir Mamun Majumder, MSc,BPharm, Raija Silvennoinen, MD, Pekka Antilla, David Tamborero, Samuli Eldfors, MSc, Riikka Karjalainen, MSc, Heikki Kuusanmäki, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Marjanna Säily, Bhagwan Yadav, MSc, Krister Wennerberg, PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 2046.

https://doi.org/10.1182/blood.V124.21.2046.2046

Published: 2014

Journal Articles

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Raya Mawad, MD, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Bart L Scott, MD, Brent L. Wood, MD PhD, Carol Dean, MPH, BSN, Vicky Sandhu, MD MPH, H. Joachim Deeg, MD, Roland B. Walter, MD PhD MS, Lixia Wang, PhD, Jack Singer, MD, Elihu H. Estey, MD, John Pagel, MD PhD

Blood (2014) 124 (21): 3690.

https://doi.org/10.1182/blood.V124.21.3690.3690

Published: 2014

Journal Articles

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

Raya Mawad, MD, Pamela S. Becker, MD, PhD, Paul C. Hendrie, MD, PhD, Bart L Scott, MD, Brent L. Wood, MD, PhD, Carol Dean, RN, Ravinder K Sandhu, MD, H. Joachim Deeg, MD, Roland B. Walter, MD, PhD, Frederick R. Appelbaum, MD, Lixia Wang, PhD, Han Myint, MD, Jack Singer, MD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2013) 122 (21): 3926.

https://doi.org/10.1182/blood.V122.21.3926.3926

Published: 2013

Journal Articles

A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS

Courtney D. DiNardo, MD, Hagop M Kantarjian, MD, Farhad Ravandi, MD, Marina Konopleva, MD, PhD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Naval G. Daver, MD, Menda Durand, MSN, RN, Silvia Rivera, MS, Alfonso Quintás-Cardama, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2698.

https://doi.org/10.1182/blood.V122.21.2698.2698

Published: 2013

Journal Articles

Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells

Chirag Acharya, Mike Y Zhong, B.S., Daniel Tannenbaum, B.S., Michelle Chen, Matt Ma, Jack Singer, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Yu-Tzu Tai, PhD

Blood (2012) 120 (21): 1847.

https://doi.org/10.1182/blood.V120.21.1847.1847

Published: 2012

Journal Articles

Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia

Jorge E. Cortes, Eric J Feldman, MD, Karen Yee, MD, David A. Rizzieri, MD, Anjali S. Advani, MD, Anthony Charman, PhD, Martin J. Toal, FFPM, Hagop M. Kantarjian

Blood (2011) 118 (21): 767.

https://doi.org/10.1182/blood.V118.21.767.767

Published: 2011

Journal Articles

A Novel Mouse Model of Multiple Myeloma Representative of Human Disease and Its Use in Preclinical Therapeutic Assessment

Rosemary A Fryer, PhD, Timothy J Graham, BSc, Emma M Smith, PhD, Brian A Walker, PhD, Gareth J Morgan, MD PhD, Simon P Robinson, PhD, Faith E Davies, MD

Blood (2011) 118 (21): 2907.

https://doi.org/10.1182/blood.V118.21.2907.2907

Published: 2011

Journal Articles

Methionine aminopeptidase 2 is required for HSC initiation and proliferation

Alvin C. H. Ma, Tsz K. Fung, Rachel H. C. Lin, Martin I. S. Chung, Dan Yang, Stephen C. Ekker, Anskar Y. H. Leung

Blood (2011) 118 (20): 5448–5457.

https://doi.org/10.1182/blood-2011-04-350173

Published: 2011

Includes: Multimedia, Supplemental data

Journal Articles

A Polymorphism in the XPNPEP2 Gene Is Associated with the Development of Hypotensive Transfusion Reactions without ACE Inhibitors.

Yiang Hui, Christopher Tormey, MD, Yanyun Wu, MD, PhD

Blood (2009) 114 (22): 3140.

https://doi.org/10.1182/blood.V114.22.3140.3140

Published: 2009

Journal Articles

Targeting Tissue Factor to Tumor Vessels. Experimental Results and First-in-Man Experience.

Wolfgang E Berdel, MD, Torsten Kessler, MD, Christian Schwöppe, PhD, Ruediger Liersch, MD, Torsten Persigehl, MD, Christoph Bremer, MD, Christoph Schliemann, MD, Rolf Mesters, MD

Blood (2009) 114 (22): 469.

https://doi.org/10.1182/blood.V114.22.469.469

Published: 2009

Journal Articles

Inhibition of HDACs and Aminopeptidases Is Highly Synergistic in Myeloma Cells Resulting in Cell Death Via the Upregulation of BIRC3, a Key Mediator of NF-KappaB Signalling.

Emma M Smith, PhD, Brian A Walker, PhD, Emma L Davenport, PhD, Lauren I Aronson, BSc.Hons., David Krige, PhD, Leon Hooftman, MD, Alan Drummond, PhD, Gareth J Morgan, MD, PhD, Faith Davies, MD

Blood (2009) 114 (22): 607.

https://doi.org/10.1182/blood.V114.22.607.607

Published: 2009

NARROW

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

MetAP2 Inhibition Modifies Hemoglobin S (HbS) to Delay Polymerization and Improve Blood Flow in Sickle Cell Disease

Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells

OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS

The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data

Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML

How I treat refractory and early relapsed acute myeloid leukemia

Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS

Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells

Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia

A Novel Mouse Model of Multiple Myeloma Representative of Human Disease and Its Use in Preclinical Therapeutic Assessment

Methionine aminopeptidase 2 is required for HSC initiation and proliferation

A Polymorphism in the XPNPEP2 Gene Is Associated with the Development of Hypotensive Transfusion Reactions without ACE Inhibitors.

Targeting Tissue Factor to Tumor Vessels. Experimental Results and First-in-Man Experience.

Inhibition of HDACs and Aminopeptidases Is Highly Synergistic in Myeloma Cells Resulting in Cell Death Via the Upregulation of BIRC3, a Key Mediator of NF-KappaB Signalling.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only